Feedback

Research progress of interleukin-15 in cancer immunotherapy

Affiliation
School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicine ,Macau University of Science and Technology ,Macau ,Macau SAR, China
Cai, Menghan;
Affiliation
Minhang Hospital and Department of Biological Medicines at School of Pharmacy ,Fudan University ,Shanghai ,China
Huang, Xuan;
Affiliation
Minhang Hospital and Department of Biological Medicines at School of Pharmacy ,Fudan University ,Shanghai ,China
Huang, Xiting;
Affiliation
Minhang Hospital and Department of Biological Medicines at School of Pharmacy ,Fudan University ,Shanghai ,China
Ju, Dianwen;
Affiliation
School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicine ,Macau University of Science and Technology ,Macau ,Macau SAR, China
Zhu, Yi Zhun;
Affiliation
School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicine ,Macau University of Science and Technology ,Macau ,Macau SAR, China
Ye, Li

Interleukin-15 (IL-15) is a cytokine that belongs to the interleukin-2 (IL-2) family and is essential for the development, proliferation, and activation of immune cells, including natural killer (NK) cells, T cells and B cells. Recent studies have revealed that interleukin-15 also plays a critical role in cancer immunotherapy. Interleukin-15 agonist molecules have shown that interleukin-15 agonists are effective in inhibiting tumor growth and preventing metastasis, and some are undergoing clinical trials. In this review, we will summarize the recent progress in interleukin-15 research over the past 5 years, highlighting its potential applications in cancer immunotherapy and the progress of interleukin-15 agonist development.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Cai, Huang, Huang, Ju, Zhu and Ye.

Use and reproduction: